Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page

NCL Method STE-3

Mycoplasma is a form of bacteria that lacks a nucleus and a cell wall, and are thus unaffected by many antibiotics. Nanoparticles submitted to the NCL may be subjected to testing for mycoplasma when deemed necessary. The types of nanoparticle...

Listed in Datasets | publication by group NCL Protocols

Version 2.0 - published on 27 Jan 2020 doi:10.17917/QCFR-6F07 - cite this Last public release: 3.0

Licensed under these terms


The NCL does not perform mycoplasma testing in our laboratory. Rather, this test is
outsourced to another department within the Frederick National Laboratory for Cancer Research,
the Protein Expression Laboratory (PEL), within the Cancer Research Technology Program.
Briefly, the NCL will culture nanoparticles with cells for the initial 24 hours, then
passage these cells twenty five (25) times. The supernatants from the final culture will then be
transported to PEL for mycoplasma testing via the VenorGem Mycoplasma PCR-based
Detection Kit from Minerva Biolab

Content List

Cite this work

Researchers should cite this work as follows:


Powered by ...

NCL Protocols

NCL Protocols group image

When watching a publication, you will be notified when a new version is released.